Page 26 - Human Use News Today

Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development pr

The Pharmaceutical Journal from the Royal Pharmaceutical Society

In todays Research Roundup for December 21, 2023, we highlight some of the most interesting reads in global health research and development from the past week.

The Santa Claus rally continues as the S&P 500 rose for the seventh straight week.

NEW YORK, Dec. 19, 2023 -- Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and...

Santhera’s AGAMREE (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy

Anavex Life Sciences Corp. (AVXL) shares went up by 11% on Tuesday following the announcement that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has approved their oral blarcamesine for Alzheimer's disease, making it eligible for submission of a Union Marketing Authorisation application in the EU.

By Sabela Ojea Shares of Anavex Life Sciences climbed on Tuesday after the company said it can submit a marketing authorization review application to the...

Anavex Life Sciences Corp. announced that the Committee for Medicinal Products for Human Use within the European Medicines Agency agreed that oral blarcamesine for Alzheimers disease is eligible...

In this article, we discuss the 13 most promising healthcare stocks according to analysts.